Clinical Trial: A Phase 3 Study to Investigate the Efficacy and Safety of EG1206A (EirGenix' Pertuzumab) Compared with EU-sourced Perjeta(R) (Pertuzumab) in Patients with HER2-positive Hormone Receptor Negative Early Breast Cancer.

U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT06884254) titled 'A Phase 3 Study to Investigate the Efficacy and Safety of EG1206A (EirGenix' Pertuzumab) Compared with EU-sourced Perjeta(R) (Pertuzumab) in Patients with HER2-positive Hormone Receptor Negative Early Breast Cancer.' on March 18.

Brief Summary: The purpose of this research study is to compare the efficacy and safety of EG1206A with Perjeta in combination with trastuzumab and chemotherapy as neoadjuvant treatment for 18 weeks, followed by surgery and subsequent EG1206A or Perjeta in combination with trastuzumab, as adjuvant treatment for 36 weeks.

Study Start Date: May, 2025

Study Type: INTERVENTIONAL

Condition: Early Breast Can...